The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
Abstract
Retrospective studies have demonstrated that patients who are expressors of cytochrome P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough concentration (C(0)). The aim of this study was to evaluate this effect prospectively by pretransplantation adaptation. We randomly assigned 280 renal transplant recipients to receive tacrolimus either according to CYP3A5 genotype or according to the standard daily regimen. The primary end point was the proportion of patients within the targeted C(0). Secondary end points included the number of dose modifications and the delay in achieving the targeted C(0). In the group receiving the adapted dose, a higher proportion of patients had values within the targeted C(0) at day 3 after initiation of tacrolimus (43.2% vs. 29.1%; P = 0.03); they required fewer dose modifications, and the targeted C(0) was achieved by 75% of these patients more rapidly. The clinical end points were similar in the two groups. Pharmacogenetic adaptation of the daily dose of tacrolimus is associated with improved achievement of the target C(0). Whether this improvement will affect clinical outcomes requires further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Wallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468
Self-citationMargreiter, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07875-3 · Cited by 450
Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., Malaise, J., Lison, D., Squifflet, J.-P., & Wallemacq, P. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00002 · Cited by 447
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
Macphee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2002) · Transplantation · doi:10.1097/00007890-200212150-00002 · Cited by 315
Genetic Variability in CYP3A5 and its Possible Consequences
Xie, H.-G., Wood, A. J., Kim, R. B., Stein, C. M., & Wilkinson, G. R. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.243.29833 · Cited by 302
Anglicheau, D., Verstuyft, C. A. A., Laurent-Puig, P., Becquemont, L., Schlageter, M.-H. A. A. G. A., Cassinat, B., Beaune, P., Legendre, C., & Thervet, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000073901.94759.36 · Cited by 281
Self-citationMacPhee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00435.x · Cited by 258
The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
Mancinelli, L. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113183 · Cited by 206
Cited by
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
PharmGKB summary: cyclosporine and tacrolimus pathways
Barbarino, J. M., Staatz, C. E., Venkataramanan, R., Klein, T. E., & Altman, R. B. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328364db84 · Cited by 257
Tang, J., Liu, R., Zhang, Y.-L., Liu, M.-Z., Hu, Y.-F., Shao, M.-J., Zhu, L.-J., Xin, H.-W., Feng, G.-W., Shang, W.-J., et al. (2017) · Scientific Reports · doi:10.1038/srep42192 · Cited by 154
Andrews, L. M., Li, Y., De Winter, B. C. M., Shi, Y.-Y., Baan, C. C., Van Gelder, T., & Hesselink, D. A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1395413 · Cited by 142
Metadata
- Authors
- Thervet, E., Loriot, M. A., Barbier, S., Buchler, M., Ficheux, M., Choukroun, G., Toupance, O., Touchard, G., Alberti, C., Le Pogamp, P., Moulin, B., Le Meur, Y., Heng, A. E., Subra, J. F., Beaune, P., & Legendre, C.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-04-14
- Volume
- 87
- Issue
- 6
- Pages
- 721-6
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1991267023
- Cited by
- 369
- References
- 17
- FWCI
- 21.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing. https://app.cochat.ai/papers/10.1038/clpt.2010.17
- The paper
- Thervet, E., Loriot, M. A., Barbier, S., Buchler, M., Ficheux, M., Choukroun, G., Toupance, O., Touchard, G., Alberti, C., Le Pogamp, P., Moulin, B., Le Meur, Y., Heng, A. E., Subra, J. F., Beaune, P., & Legendre, C. (2010). Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2010.17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.